PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11518857-1 2001 OBJECTIVE: We recently reported that treatment of uremic rats with reduced renal mass with the angiotensin II (Ang II) subtype 1 receptor (AT1) antagonist losartan reduces endothelin-1 (ET-1) levels in blood vessels and in glomeruli. Losartan 155-163 endothelin 1 Rattus norvegicus 172-184 11518857-1 2001 OBJECTIVE: We recently reported that treatment of uremic rats with reduced renal mass with the angiotensin II (Ang II) subtype 1 receptor (AT1) antagonist losartan reduces endothelin-1 (ET-1) levels in blood vessels and in glomeruli. Losartan 155-163 endothelin 1 Rattus norvegicus 186-190 11518857-9 2001 Treatment of uremic rats with the TRx or with losartan reduced ET-1 content in the thoracic aorta and the mesenteric arterial bed (P < 0.01). Losartan 46-54 endothelin 1 Rattus norvegicus 63-67 11518857-10 2001 However, losartan, but not the TRx, significantly attenuated the rise of serum creatinine, proteinuria and urinary ET-1 and TGF-beta1 excretion, as well as ET-1 content in glomeruli of uremic rats. Losartan 9-17 endothelin 1 Rattus norvegicus 115-119 11518857-10 2001 However, losartan, but not the TRx, significantly attenuated the rise of serum creatinine, proteinuria and urinary ET-1 and TGF-beta1 excretion, as well as ET-1 content in glomeruli of uremic rats. Losartan 9-17 endothelin 1 Rattus norvegicus 156-160 11518857-12 2001 Treatment of uremic rats with losartan prevented renal preproET-1 mRNA overexpression, indicating that changes in glomerular ET-1 content and urinary ET-1 excretion were related to modulation of renal ET-1 production. Losartan 30-38 endothelin 1 Rattus norvegicus 61-65 11518857-12 2001 Treatment of uremic rats with losartan prevented renal preproET-1 mRNA overexpression, indicating that changes in glomerular ET-1 content and urinary ET-1 excretion were related to modulation of renal ET-1 production. Losartan 30-38 endothelin 1 Rattus norvegicus 125-129 11518857-12 2001 Treatment of uremic rats with losartan prevented renal preproET-1 mRNA overexpression, indicating that changes in glomerular ET-1 content and urinary ET-1 excretion were related to modulation of renal ET-1 production. Losartan 30-38 endothelin 1 Rattus norvegicus 125-129 11518857-13 2001 CONCLUSIONS: These findings indicate that the effect of losartan on ET-1 production in peripheral blood vessels may be mediated, in part, by the reduction of blood pressure. Losartan 56-64 endothelin 1 Rattus norvegicus 68-72 11518857-14 2001 In contrast, the reduction of renal ET-1 production is mediated by tissue-specific effects of AT1 receptor blockade, and may contribute to the renal protective effects of losartan. Losartan 171-179 endothelin 1 Rattus norvegicus 36-40 9715793-0 1998 Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Losartan 11-19 endothelin 1 Rattus norvegicus 37-49 10844136-3 2000 We also studied the effects a two-week oral pre-treatment with losartan (10 mg/kg/day) or enalapril (25 mg/kg/day) on endothelin-1-induced changes in the hypotensive responses to bradykinin. Losartan 63-71 endothelin 1 Rattus norvegicus 118-130 10844136-7 2000 Endothelin-1 also decreased (P<0.05) the responses to bradykinin in rats pre-treated with losartan, but had no effect in rats pre-treated with enalapril. Losartan 93-101 endothelin 1 Rattus norvegicus 0-12 10535660-10 1999 Losartan also normalized the increased ir-ET-1 concentration in plasma and in the thoracic aorta, but had no effect on tissues with normal or reduced ir-ET-1 levels. Losartan 0-8 endothelin 1 Rattus norvegicus 42-46 10535660-13 1999 The reduction of systolic blood pressure by losartan supports a role for AngII in the pathogenesis of this form of hypertension, which may be due, at least in part, to the modulation of ET-1 production. Losartan 44-52 endothelin 1 Rattus norvegicus 186-190 9715793-9 1998 Treatment of uremic rats with losartan or captopril reduced irET-1 concentration in the thoracic aorta and preglomerular arteries (P < .05), but ir-ET-1 concentration in the mesenteric arterial bed was unchanged. Losartan 30-38 endothelin 1 Rattus norvegicus 62-66 9715793-10 1998 Although both drugs completely prevented the increase in proteinuria, losartan but not captopril significantly reduced ir-ET-1 concentration in glomeruli (P < .05) and normalized urinary ir-ET-1 excretion. Losartan 70-78 endothelin 1 Rattus norvegicus 122-126 9715793-10 1998 Although both drugs completely prevented the increase in proteinuria, losartan but not captopril significantly reduced ir-ET-1 concentration in glomeruli (P < .05) and normalized urinary ir-ET-1 excretion. Losartan 70-78 endothelin 1 Rattus norvegicus 193-197 9715793-12 1998 The beneficial effects of the AT1 antagonist losartan could be attributable to the attenuation of Ang II-induced ET-1 production in this rat remnant kidney model of chronic renal failure, whereas those of the ACE-I captopril are not related to changes in ET-1 production in glomeruli. Losartan 45-53 endothelin 1 Rattus norvegicus 113-117 9715793-12 1998 The beneficial effects of the AT1 antagonist losartan could be attributable to the attenuation of Ang II-induced ET-1 production in this rat remnant kidney model of chronic renal failure, whereas those of the ACE-I captopril are not related to changes in ET-1 production in glomeruli. Losartan 45-53 endothelin 1 Rattus norvegicus 255-259 7620700-10 1995 The IC50 values of LR-B/081 and losartan obtained against vasoconstriction induced by endothelin-1 and noradrenaline were two orders of magnitude higher. Losartan 32-40 endothelin 1 Rattus norvegicus 86-98 9622146-0 1998 Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Losartan 0-8 endothelin 1 Rattus norvegicus 66-78 9622146-11 1998 Although both antihypertensive agents lowered blood pressure and normalized endothelial function, only losartan prevented the increase in tissue endothelin-1 content, suggesting that angiotensin type 1 receptor antagonists but not calcium antagonists modulate tissue endothelin-1 in vivo. Losartan 103-111 endothelin 1 Rattus norvegicus 145-157 9488222-0 1997 Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide. Losartan 0-8 endothelin 1 Rattus norvegicus 42-54 9488222-5 1997 RESULTS: Pre-incubation with losartan significantly reduced the contractile response to endothelin-1 compared with control rings, without modifying the value represented by 50% of the maximal response (pD2). Losartan 29-37 endothelin 1 Rattus norvegicus 88-100 9488222-8 1997 The diminished response to both endothelin-1 and U46619 in the presence of losartan was reversed in L-NAME-pretreated rings. Losartan 75-83 endothelin 1 Rattus norvegicus 32-44 9488222-9 1997 CONCLUSIONS: Angiotensin II seems to participate in the vasoconstriction induced by both endothelin-1 and the thromboxane A2 analogue through the stimulation of AT1 receptors in SHR aortic rings, because losartan inhibited this effect. Losartan 204-212 endothelin 1 Rattus norvegicus 89-101 8950291-2 1996 Preinjection (10 min before) of losartan (a selective AT1 receptor antagonist; 50 nmol) to the PAG area reduced the behavioural response to ET-1. Losartan 32-40 endothelin 1 Rattus norvegicus 140-144 7498249-5 1995 Losartan (10 mg/kg/day p.o., 2 weeks) significantly reduced left ventricular weight and left ventricular endothelin-1 level in the rats with aortic insufficiency without affecting blood pressure and there was a significant positive correlation between left ventricular weight and left ventricular endothelin-1 content. Losartan 0-8 endothelin 1 Rattus norvegicus 105-117 7498249-5 1995 Losartan (10 mg/kg/day p.o., 2 weeks) significantly reduced left ventricular weight and left ventricular endothelin-1 level in the rats with aortic insufficiency without affecting blood pressure and there was a significant positive correlation between left ventricular weight and left ventricular endothelin-1 content. Losartan 0-8 endothelin 1 Rattus norvegicus 297-309 8613264-8 1996 Thus, the AT1 receptor antagonist losartan and the angiotensin-converting enzyme inhibitors quinaprilat and captopril diminished the ET-1-mediated effects, whereas, the ETA receptor antagonist BQ-123 diminished the Ang II-induced fibronectin synthesis and mesangial cell proliferation. Losartan 34-42 endothelin 1 Rattus norvegicus 133-137 8170471-9 1994 The release of total inositol phosphates in response to ET-1 and AII was concentration dependent and inhibited by the ETA receptor-selective antagonist BQ-123 and the AT1 receptor-selective antagonist losartan, respectively. Losartan 201-209 endothelin 1 Rattus norvegicus 56-68 8184972-9 1994 The transient endothelium-mediated relaxing phase of the depressor response to systemic injections of endothelin-1 was attenuated by losartan and lisinopril in TG rats. Losartan 133-141 endothelin 1 Rattus norvegicus 102-114 32899487-8 2020 RESULTS: Preincubation with L-NAME induced dose-dependent vasoconstriction via endothelin-1 in the non-SAH cohort, which was dose-dependently reduced by losartan. Losartan 153-161 endothelin 1 Rattus norvegicus 79-91 32899487-12 2020 Losartan alleviated the maximum contraction triggered by endothelin-1. Losartan 0-8 endothelin 1 Rattus norvegicus 57-69 20666571-9 2010 Aliskiren and losartan at the doses used depressed similarly the levels of ANG II in cortex and papilla and reduced ET-1 significantly in the renal cortex and papilla below control levels in HanSD rats. Losartan 14-22 endothelin 1 Rattus norvegicus 116-120 24760983-7 2014 In addition, the enhanced expression of Gqalpha/PLC-beta1 proteins, enhanced phosphorylation of ERK1/2, and enhanced protein synthesis in VSMC from SHR were attenuated by the ANG II AT1 and endothelin-1 (ET-1) ETA receptor antagonists losartan and BQ123, respectively, but not by the ETB receptor antagonist BQ788. Losartan 235-243 endothelin 1 Rattus norvegicus 190-202 24760983-7 2014 In addition, the enhanced expression of Gqalpha/PLC-beta1 proteins, enhanced phosphorylation of ERK1/2, and enhanced protein synthesis in VSMC from SHR were attenuated by the ANG II AT1 and endothelin-1 (ET-1) ETA receptor antagonists losartan and BQ123, respectively, but not by the ETB receptor antagonist BQ788. Losartan 235-243 endothelin 1 Rattus norvegicus 204-208 23988026-6 2013 Under losartan the ET-1 induced contraction is decreased. Losartan 6-14 endothelin 1 Rattus norvegicus 19-23 23988026-8 2013 In precontracted vessels under losartan and BQ-123, an ET(A)-receptor antagonist, ET-1 induced a higher relaxation. Losartan 31-39 endothelin 1 Rattus norvegicus 82-86 23988026-11 2013 Losartan has a dose-dependent antagonistic effect to the ET-1 induced contraction, which seems to ET(B)-receptor dependent. Losartan 0-8 endothelin 1 Rattus norvegicus 57-61 28756589-1 2018 Under physiologic conditions, losartan showed a dose-dependent antagonistic effect to the endothelin-1 (ET-1)-mediated vasoconstriction. Losartan 30-38 endothelin 1 Rattus norvegicus 90-102 28756589-1 2018 Under physiologic conditions, losartan showed a dose-dependent antagonistic effect to the endothelin-1 (ET-1)-mediated vasoconstriction. Losartan 30-38 endothelin 1 Rattus norvegicus 104-108 28756589-8 2018 Parallel to physiological conditions, after SAH, the ET-1-induced vasoconstriction was decreased by preincubation with losartan. Losartan 119-127 endothelin 1 Rattus norvegicus 53-57 28756589-10 2018 In precontracted vessels, ET-1 induced a higher vasorelaxation under losartan and the endothelin A receptor (ET(A)-receptor) antagonist BQ-123. Losartan 69-77 endothelin 1 Rattus norvegicus 26-30 28756589-14 2018 Also, the dose-dependent antagonistic effect to the ET-1-induced contraction can be effected by angiotensin II type 1 receptor (AT1-receptor) antagonism due to losartan directly via the ET(B1)-receptor. Losartan 160-168 endothelin 1 Rattus norvegicus 52-56 20026366-5 2010 Mesenteric arteries isolated from such GK rats following treatment with losartan (25mg/kg/day for 2 weeks) exhibited reduced ET-1- and Ang II-induced contractions, suppressed ET-1-stimulated ERK phosphorylation, and increased ACh-induced relaxation, while the rats exhibited normalized plasma NO metabolism and their mesenteric arteries exhibited increased basal NO formation. Losartan 72-80 endothelin 1 Rattus norvegicus 125-141 19029977-7 2008 The systolic blood pressure and endothelin-1-induced contractile responses in aortae in vitro were enhanced in insulin-treated diabetic rats and blunted by chronic losartan administration. Losartan 164-172 endothelin 1 Rattus norvegicus 32-44 16229907-13 2005 ET-1 levels were also reversed to the normal values with the losartan treatment. Losartan 61-69 endothelin 1 Rattus norvegicus 0-4 17487457-3 2007 After losartan treatment for 12 weeks, we observed by immunofluorescence that the vascular AGE level in the losartan group was significantly lower than that of the SHR group and that the vascular mRNA expression of RAGE, NF-kappaB, NADPH oxidase p47phox and ET-1, as detected by RT-PCR, was significantly lower in losartan group than in the SHR group. Losartan 108-116 endothelin 1 Rattus norvegicus 258-262 17487457-3 2007 After losartan treatment for 12 weeks, we observed by immunofluorescence that the vascular AGE level in the losartan group was significantly lower than that of the SHR group and that the vascular mRNA expression of RAGE, NF-kappaB, NADPH oxidase p47phox and ET-1, as detected by RT-PCR, was significantly lower in losartan group than in the SHR group. Losartan 108-116 endothelin 1 Rattus norvegicus 258-262 16229907-17 2005 Na and Cr excretions were decreased, while proteinuria and plasma ET-1 levels were normalized by losartan treatment, suggesting that renin-angiotensin system activation may have a role in leptin induced renal changes. Losartan 97-105 endothelin 1 Rattus norvegicus 66-70 16191423-7 2005 This study suggested that blocking RAS using Benazepril or Losartan can have protective effects on the renal injury in glomerulosclerosis by down-regulating the expressions of TGF-beta1, Col IV, Fn, ET-1 and iNOS. Losartan 59-67 endothelin 1 Rattus norvegicus 199-212 16410221-11 2005 In conclusion, coadministration of insulin and losartan in nonhypertensive animals suffering from diabetes type 1 may offer new cardiac protection benefits by improving coronary blood flow and cardiomyocyte contractility through modulating ET-1 receptor subtypes density and affinity at CE and CM sites. Losartan 47-55 endothelin 1 Rattus norvegicus 240-244 15056982-7 2004 Vasoconstriction to endothelin-1 was reduced by losartan in NX and Sham rats. Losartan 48-56 endothelin 1 Rattus norvegicus 20-32 15056982-10 2004 CONCLUSION: Losartan reduced conduit artery vasoconstriction to endothelin-1 and augmented vasorelaxation via K+ channels in NX rats, although blood pressure and renal function were unchanged. Losartan 12-20 endothelin 1 Rattus norvegicus 64-76 12947726-6 2003 In Losartan treatment group, all of MPA, 24 hours urine protein count, kidney weight/body weight and Ccr decreased, compared with those of model group; ET-1 in blood and urine decreased too, especially the decreasing of ET-1 in urine (P < 0.01). Losartan 3-11 endothelin 1 Rattus norvegicus 152-156 12947726-6 2003 In Losartan treatment group, all of MPA, 24 hours urine protein count, kidney weight/body weight and Ccr decreased, compared with those of model group; ET-1 in blood and urine decreased too, especially the decreasing of ET-1 in urine (P < 0.01). Losartan 3-11 endothelin 1 Rattus norvegicus 220-224 12947726-8 2003 CONCLUSION: Losartan may play a role in inhibiting the synthesis and secretion of ET-1 in kidney and thus it will contribute to the decreasing of proteinuria and the protection of renal function. Losartan 12-20 endothelin 1 Rattus norvegicus 82-86